Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

61. Nivolumab (Opdivo), pembrolizumab (Keytruda): reports of organ transplant rejection

Nivolumab (Opdivo), pembrolizumab (Keytruda): reports of organ transplant rejection Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection - GOV.UK GOV.UK uses cookies to make the site simpler. Search Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection There have been reports of rejection of solid organ transplants in patients treated with nivolumab or pembrolizumab. Ipilimumab (Yervoy▼) may also interfere with immunosuppressive (...) therapy, increasing the risk of graft rejection. Published 20 July 2017 From: Therapeutic area: , , Contents Advice for healthcare professionals: rejection of solid organ transplants, including renal and corneal grafts, has been reported in the post-marketing setting in patients treated with programmed death receptor 1 (PD-1) inhibitors consider the benefit of treatment with nivolumab or pembrolizumab versus the risk of possible organ transplant rejection for each patient some cases of rejection

2017 MHRA Drug Safety Update

62. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma Niv Nivolumab for treating relapsed or olumab for treating relapsed or refr refractory classical Hodgkin lymphoma actory classical Hodgkin lymphoma T echnology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta462 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 28Contents Contents 1

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

63. Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy)

Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies (...) . This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) July 2017 Nivolumab is a drug which blocks a protein, called the programmed death-1 (PD-1) receptor, on the surface of certain immune cells

2017 NIHR Innovation Observatory

64. High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma (Full text)

High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma Autoimmune neutropenia is a rare side effect of nivolumab which may respond to antibody-based therapies.Nivolumab can lead to durable complete remission in primary mediastinal B-cell lymphoma refractory to multiple lines of therapy.

2017 Blood advances PubMed

65. [Nivolumab for the treatment of advanced melanoma]

[Nivolumab for the treatment of advanced melanoma] [Nivolumab for the treatment of advanced melanoma] [Nivolumab for the treatment of advanced melanoma] González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation González L, Pichon-Riviere A, Augustovski F (...) , García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Nivolumab for the treatment of advanced melanoma] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 543. 2017 Authors' conclusions High quality evidence showed that the use of nivolumab as first-line therapy, in patients with advanced (metastatic or irresecable) melanoma without BRAF mutations would increase the rate of one year progression

2017 Health Technology Assessment (HTA) Database.

66. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. (Full text)

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC.We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level (...) of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level of 5% or more.Among

2017 NEJM PubMed

67. Nivolumab (Hodgkin lymphoma) - Benefit assessment according to õ35a Social Code Book V

Nivolumab (Hodgkin lymphoma) - Benefit assessment according to õ35a Social Code Book V Nivolumab (klassisches Hodgkin-Lymphom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-76 [Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V] Nivolumab (klassisches Hodgkin-Lymphom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-76 [Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V] Institut für (...) Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (klassisches Hodgkin-Lymphom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-76. [Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a

2017 Health Technology Assessment (HTA) Database.

68. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. (Full text)

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and efficacy of nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic viral (...) hepatitis.We did a phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040) of nivolumab in adults (≥18 years) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or B (HCV or HBV) infection. Previous sorafenib treatment was allowed. A dose-escalation phase was conducted at seven hospitals or academic centres in four countries or territories (USA, Spain, Hong Kong, and Singapore) and a dose-expansion phase was conducted

2017 Lancet PubMed

69. Nivolumab (new therapeutic indication)

Nivolumab (new therapeutic indication) Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Nivolumab (nicht plattenepitheliales NSCLC) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 July 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A16-25 Nivolumab (non-squamous NSCLC) – Benefit assessment (...) according to §35a Social Code Book V 1 Extract of dossier assessment A16-25 Version 1.0 Nivolumab (non-squamous NSCLC) 28 July 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (non-squamous NSCLC) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 2 May 2016 Internal Commission No.: A16-25 Address of publisher

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

70. Nivolumab (new therapeutic indication)

Nivolumab (new therapeutic indication) Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Nivolumab (Nierenzellkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 July 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A16-24 Nivolumab (renal cell carcinoma) – Benefit assessment according (...) to §35a Social Code Book V 1 Extract of dossier assessment A16-24 Version 1.0 Nivolumab (renal cell carcinoma) 28 July 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 2 May 2016 Internal Commission No.: A16-24 Address of publisher

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

71. Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment (Full text)

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment A 62-year-old Japanese female with primary lung adenocarcinoma received seven cycles of nivolumab as an eighth line of chemotherapy until she presented with hemoptysis. After transcatheter arterial embolization therapy, she received subsequent chemotherapy with paclitaxel and S-1. Four weeks later, a chest computed tomography examination revealed infiltrative (...) resembles manifestation of pseudoprogression during treatments with immune checkpoint inhibitors, such as nivolumab.© 2017 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2017 Thoracic cancer PubMed

72. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab (Full text)

Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab Nivolumab, a monoclonal antibody to programmed cell death protein-1 (PD-1), has revolutionised the management of patients with advanced non-small cell lung cancer (NSCLC). Treatment with nivolumab is associated with toxicities known as immune-related adverse events. Although pneumonitis is a potentially serious event, little is known of its clinical (...) and radiographic features. We here report a case of NSCLC for which treatment with nivolumab resulted in the development of ground-glass opacity surrounding the primary lung tumour and an associated increase in tumour size. Administration of prednisone led to rapid resolution of both clinical symptoms and the abnormal shadow on the lung field as well as shrinkage of the tumour. However, retreatment with nivolumab induced clinical and radiographic manifestations similar to those triggered by the first challenge

2017 ESMO open PubMed

73. Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis (Full text)

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis 29147577 2019 01 30 2059-7029 2 Suppl 1 2017 ESMO open ESMO Open Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis. e000119 10.1136/esmoopen-2016-000119 Vansteenkiste Johan J Respiratory Oncology Unit, Department of Respiratory Medicine, Katholieke Universiteit Leuven, Leuven, Belgium. eng Editorial 2017 03 07 England ESMO Open 101690685 2059-7029 2016 11 27 2017 01 11 2016

2017 ESMO open PubMed

74. Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer (Full text)

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of nivolumab in Japanese patients with advanced or recurrent non-squamous NSCLC.In this multicentre phase II study, patients with advanced (...) or recurrent non-squamous NSCLC, which had progressed after platinum-containing chemotherapy, were treated with nivolumab 3 mg/kg, intravenously every 2 weeks until progressive disease or unacceptable toxicity was observed. The primary end point was independent radiology review committee (IRC) assessed overall response rate (ORR) and the secondary endpoints included ORR (investigator assessed), progression-free survival (PFS), overall survival (OS), duration of response, time to response, best overall

2017 ESMO open PubMed

75. [Nivolumab (renal cell carcinoma) - addendum to commission A16-24]

[Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56 [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56 [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56. [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 438. 2016 Final publication URL Indexing Status

2017 Health Technology Assessment (HTA) Database.

76. [Nivolumab (NSCLC) - addendum to commission A16-25]

[Nivolumab (NSCLC) - addendum to commission A16-25] Nivolumab (nicht plattenepitheliales NSCLC): addendum zum auftrag A16-25; auftrag A15-57 [Nivolumab (NSCLC) - addendum to commission A16-25] Nivolumab (nicht plattenepitheliales NSCLC): addendum zum auftrag A16-25; auftrag A15-57 [Nivolumab (NSCLC) - addendum to commission A16-25] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nicht plattenepitheliales NSCLC): addendum zum auftrag A16-25; auftrag A15-57. [Nivolumab (NSCLC) - addendum to commission A16-25] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 439. 2016 Final publication URL Indexing Status Subject indexing

2017 Health Technology Assessment (HTA) Database.

77. Nivolumab in advanced melanoma treament

Nivolumab in advanced melanoma treament Nivolumab in advanced melanoma treament Nivolumab in advanced melanoma treament Tapia-López E, Ciapponi A, Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L Citation Tapia-López E, Ciapponi A, Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L. Nivolumab in advanced melanoma treament. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (...) (IECS). Informe de Respuesta Rapida No. 480. 2016 Authors' conclusions Moderate quality evidence showed that the use of nivolumab, when compared with dacarbazine in patients with advanced melanoma (metastatic or inoperable) would increase survival rate at one year and progression-free survival as first line. Although its use as single-agent or in combination with ipilimumab showed an increased progression-free survival, the lack of information on its impact on overall survival or comparative studies

2017 Health Technology Assessment (HTA) Database.

78. Nivolumab for the treatment of non-small cell lung cancer

Nivolumab for the treatment of non-small cell lung cancer Nivolumab for the treatment of non-small cell lung cancer Nivolumab for the treatment of non-small cell lung cancer Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Nivolumab for the treatment of non-small cell lung cancer. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 479. 2016 Authors' conclusions The evidence on the effectiveness and safety of nivolumab as second line treatment for advanced non-small cell lung cancer, compared with docetaxel is of high quality. Nivolumab was associated

2017 Health Technology Assessment (HTA) Database.

79. OPDIVO - Nivolumab

OPDIVO - Nivolumab Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012 will be updated to include post

2017 Health Canada - Drug and Health Product Register

80. Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V

Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab (Urothelkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-29 Nivolumab (...) (urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-29 Version 1.0 Nivolumab (urothelial carcinoma) 28 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 3 July 2017

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)